Patent · US Active

Bi-specific monovalent diabodies that are capable of binding CD19 and CD3, and uses thereof

US10633443B2 · kind B2 · utility

2Cited by

27References

9Claims

0Family size

Assignee

Macrogenics, Inc. · US

Inventors

Leslie S. Johnson · Travilah, US
Ezio Bonvini · Potomac, US
Chia-Ying Kao Lam · Foster City, US
Paul A. Moore · North Potomac, US
Liqin Liu · Germantown, US
Scott Koenig · Rockville, US

Key dates

Filing date	Sep 22, 2015
Grant date	Apr 28, 2020
Priority date	—
Expiry date	Sep 24, 2035

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07K2317/94
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

CD 19×CD3 bi-specific monovalent diabodies, and particularly, CD 19×CD3 bi-specific monovalent Fc diabodies, are capable of simultaneous binding to CD 19 and CD3, and are used in the treatment of hematologic malignancies.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.